| Trial ID # | NCT00023907 |
| Phase | II |
| Drug Class | Chemotherapy |
| Drug Name | Paclitaxel |
| Alternate Drug Names | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL |
| Drugs in Trial | Paclitaxel |
| Eligible Participant | Platinum resistant or refractory ovarian cancer (after first-line platinum-based chemotherapy) |
| Patients Enrolled | 51 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, evaluated per RECIST |
| Efficacy | Weekly paclitaxel: |
| Clinically Significant Adverse Events | Serious AE; |
| Conclusion | Weekly paclitaxel shows promising activity in Pt-R and Pt-Rf patients |
| Reference | Markmann M et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 101(3): 436-40 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.